



ASX Release

22 May 2018

**ZELDA THERAPEUTICS LIMITED**  
ACN 103 782 378

Level 45  
108 St Georges Terrace,  
Perth Western Australia 6000  
Tel: +61 8 6558 0886  
Fax: +61 8 6316 3337  
E: enquiries@zeldatherapeutics.com  
W: www.zeldatherapeutics.com

#### **Contacts**

Mr Harry Karelis  
Executive Chairman  
+61 413 056 328  
hkarelis@zeldatherapeutics.com

#### **Directors**

Mr Harry Karelis  
Dr Stewart Washer  
Ms Mara Gordon  
Mr Jason Peterson

#### **Tickers:**

Australia (ASX): ZLD  
USA (OTC): ZLDAF

#### **Ordinary Shares:**

755,341,934

#### **Options:**

46,000,000

1,500,000 (\$0.04 – 6/2/2020)

\*4,500,000 (\$0.04 – 6/2/2020)

40,000,000 (\$0.03125 – 17/11/2021)

\* subject to vesting conditions

## APPOINTMENT OF MANAGING DIRECTOR

- **Dr Richard Hopkins appointed Managing Director**
- **Extensive experience in managing diverse research projects as well as public company leadership credentials**
- **Zelda now building a platform for the next phase of its growth**
- **Exceptionally well positioned to continue generating shareholder value**

**Zelda Therapeutics Ltd (ASX: ZLD, “Zelda” or the Company)** is pleased to announce that it has appointed Dr. Richard Hopkins as full-time Managing Director, commencing 1 July 2018.

Richard is an experienced bio-pharmaceutical executive with over 11 years in corporate leadership roles with public biotechnology companies. He has an established track record in drug development of novel cancer therapies and has strong experience with corporate strategy, business development and intellectual property matters. During his career, Dr. Hopkins has managed and overseen several strategic alliance and licensing deals with multiple global pharmaceutical partners.

Most recently, he was the Chief Executive Officer of PharmAust Ltd, an ASX-listed biotechnology company. Prior to that, he was Managing Director at Phylogica Ltd, a company he co-founded in 2001 where he also held a variety of other positions including Chief Scientific Officer and Chief Operating Officer.

Richard holds a PhD in Molecular Biology, is an author on over 25 peer-reviewed publications and is an inventor on 17 patents and patent applications. Dr. Hopkins currently serves as Chair of the Western Australian Ausbiotech Committee.

Zelda also announces that Dr Stewart Washer will step back from his executive position and will revert to a non-executive director of the Company.

#### **Remuneration Package**

Base Salary: \$250,000 inclusive of superannuation

Commencement date: 1 July 2018

Annual leave: 4 weeks

Notice period: 3 months

Probation period: 3 months

Options package (subject to shareholder approval):

5 million @ 15 cents per share (vesting on completion of probation period)

5 million @ 25 cents per share (vesting 12 months after completion of probation)

5 million @ 35 cents per share (vesting 12 months after completion of probation)

5 million @ 45 cents per share (vesting 24 months after completion of probation)

5 million @ 50 cents per share (vesting 24 months after completion of probation)

Options expiry: 3 years from issue date

**Executive Chairman of Zelda Harry Karelis stated:**

*“We have achieved much since our inception in 2015 and have developed deep relationships across the globe and created significant value for our shareholders. As the company prepares for its next phase of growth we are very pleased to have been able to attract someone of the calibre of Richard to join the team in a leadership position. We are in very capable hands and we will be working closely together to build on our success to date. Furthermore, the options incentive package recognises the importance of aligning the interests of management with those of shareholders.”*

**Dr Richard Hopkins stated:**

*“It is an exciting time to be joining Zelda as the company is poised to deliver on the significant pre-clinical and clinical foundations laid down in recent years. I look forward to adding value to the strategic direction of the company and accelerate plans to make its medical cannabinoid-based therapies available for patients. There are exciting times ahead for shareholders and I am delighted to be taking on the role of Managing Director of a company that is extremely well positioned in a rapidly evolving and growing global sector.”*

**Tim Slate**

**Company Secretary**

---

**About Zelda Therapeutics ([www.zeldatherapeutics.com](http://www.zeldatherapeutics.com))**

Zelda Therapeutics Ltd (“Zelda”) is an Australian-based bio-pharmaceutical company that is focused on developing a range of cannabinoid-based formulations for the treatment of a variety of medical conditions. The Company has a two-pronged strategy comprising:

- A **human clinical trial programme** focused on insomnia, autism and eczema with activities in Australia, Chile and the USA.
- A **pre-clinical research programme** examining the effect of cannabinoids in breast, brain and pancreatic cancer as well as research examining the potential for cannabinoids to treat diabetes-associated cognitive decline.

It has partnered with the world’s leading cancer cannabis researchers at Complutense University Madrid in Spain to conduct certain pre-clinical work testing cannabis-based formulations known to have an effect in humans in order to generate data packs in a form expected by regulators and the pharmaceutical industry. A similar programme is in place with the Australian Telethon Kids Institute targeting paediatric brain cancer and Curtin University targeting pancreatic cancer and cognitive decline.